Last reviewed · How we verify
Phenylephrine Ophthalmic Product
At a glance
| Generic name | Phenylephrine Ophthalmic Product |
|---|---|
| Sponsor | Wake Forest University Health Sciences |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Clinical Determinants and Adverse Reactions to Tropicamide/Phenylephrine in Hospitalized Patients.
- Phenylephrine Versus Eyelid Taping for Muller's Muscle-Conjunctival Resection (MMCR) Evaluation (PHASE4)
- Pharmacodynamics of a Fixed Dose Combination of 0.34% Tropicamide and 2.5% Phenylephrine Hydrochloride, Eye Drop, Solution (PHASE1, PHASE2)
- Evaluation of Pupil Dilation Speed With the MAP Dispenser (PHASE4)
- Effectiveness of Periocular Drug Injection in CATaract Surgery (PHASE3)
- Efficacy of the MydCombi on Pupillary Dilation in Pediatric and Adult Patients (PHASE4)
- Ketorolac Levels in Vitreous and Aqueous Samples From Patients Undergoing Combined Cataract and Pars Plana Vitrectomy Surgeries With and Without Intracameral Phenylephrine 1.0% / Ketorolac 0.3% (EARLY_PHASE1)
- The Effect of Brimonidine (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |